Lindsay Fraser

Lindsay Fraser began their work experience in 2002 at Biobest Laboratories Ltd, where they started as an assistant virologist and eventually became the Cell Culture Manager. During their time there, they gained skills in routine testing, ELISA development, and hemagglutination/inhibition assays. In 2009, they joined the Scottish National Blood Transfusion Service NHS-NSS (SNBTS) - Tissues & Cells Directorate, where they helped establish the Scottish Islet Cell Isolation Laboratory. Lindsay played a crucial role in transforming the concept derived from the 'Edmonton Protocol' into a GMP grade cellular therapy for patients with Type 1 diabetes.

In 2016, Lindsay briefly worked at Miltenyi Biotec as a Clinical Account Manager, where they provided consultancy and support for clients in the cellular immunotherapy field. Lindsay built relationships with key opinion leaders and helped GMP translate clients' R&D processes using products from the Miltenyi Biotec range. Later that year, they joined Roslin Cells as a Senior Cell Therapy Development Scientist, leading the iPSC Team and establishing the Induced Pluripotent Stem Cell (iPSC) Core Facility. Lindsay developed protocols and standard operating procedures for reprogramming somatic and progenitor cells to an embryonic-like state.

In 2017, Lindsay transitioned to RoslinCT as the Cell Therapy Development Manager. In this role, they provided leadership to the Cell Therapy Development Team, focusing on the development, GMP translation, and Technology Transfer of cell and gene therapies. Lindsay led the project management of GMP processes, generated GMP documentation, and designed QC strategies.

Starting in 2020, Lindsay joined Symbiosis Pharmaceutical Services as the Head of Technical Services. Lindsay held this position until 2022, overseeing technical operations within the company. Currently, Lindsay serves as the Chief Scientific Officer at Cytomos, a position they began in August 2022.

Lindsay Fraser completed their Bachelor's Degree in Virology and Parasitology at The University of Edinburgh from 1997 to 2001. Lindsay then pursued a PGDip (MSc) in Biomedical Science with a focus on Medical Microbiology at Anglia Ruskin University in Cambridge from 2005 to 2006. Lindsay continued their education at The University of Edinburgh from 2006 to 2009, where they obtained their Doctor of Philosophy (Ph.D.) in Medical Molecular Genetics from the John Hughes Bennett Laboratories in Queen's Medical Research.